Skip to main content
    N

    Nyxoah (NYXH)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $0.90
    +0.01 (+0.69%)

    Market Cap: $91.61M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Nyxoah (NYXH) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nyxoah (NYXH) has a market cap of $91.61M. Its share count is up 169.50% from a year earlier. Revenue grew 429.37% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$91.61M
    Latest price (Nov 17, 2026)$0.90

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 76.92% in the quarter ended Sep 30, 2026 and grew 71.29% a year over 2 years.

    Shares Outstanding100.87M
    Shares Change (YoY)+169.50%
    Shares Change (QoQ)+76.92%
    Share Count Growth (2Y CAGR)+71.29%

    Valuation Ratios

    Sales and book value multiples are 2.6x and 1.2x. Its year-end P/S ranged from 15.3x to 557.0x from 2021 to 2025.

    P/S Ratio2.6x
    P/B Ratio1.2x
    P/TBV Ratio1.2x

    Valuation history and multiples

    Price Statistics

    The stock is down 82.00% over 52 weeks and trades 23.08% below its 50-day average.

    Beta (1Y)2.45
    52-Week Change-82.00%
    1-Month Change-5.68%
    3-Month Change-45.46%
    6-Month Change-67.98%
    5-Year Change-96.53%
    Total Return (1Y)-82.00%
    Total Return (3Y CAGR)-43.61%
    Total Return (5Y CAGR)-47.59%
    Max Drawdown (1Y)-84.49%
    Max Drawdown (3Y)-95.84%
    Sharpe Ratio (1Y)-1.72
    Correlation with SPY (1Y)0.35
    50-Day Average$1.17
    200-Day Average$2.26
    52-Week Range$0.80 to $5.39
    RSI (14 Days)38.5
    Average Volume (20 Days)237.84K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.19x current liabilities, and total debt is 0.67x shareholder equity.

    Current Ratio2.19x
    Quick Ratio2.08x
    Debt / Equity0.67x
    Interest Coverage-3.57x

    Returns and Efficiency

    Return on invested capital is -65.86% over the last 12 months, against a 5-year average of -39.40%.

    Return on Equity (ROE)-138.65%
    Return on Assets (ROA)-63.36%
    Return on Invested Capital (ROIC)-65.86%
    Return on Capital Employed (ROCE)-69.52%
    ROE (5Y Average)-64.87%
    ROA (5Y Average)-37.16%
    ROIC (5Y Average)-39.40%
    Asset Turnover0.25x
    Inventory Turnover3.25x
    Receivables Turnover3.30x
    Cash Conversion Cycle-21 days

    Scores

    NYXH has an Altman Z-Score of -3.94, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-3.94
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was EUR 29.85M over the last 12 months.

    RevenueEUR 29.85M
    Revenue Growth (YoY)+429.37%
    Gross ProfitEUR 16.21M
    Operating IncomeEUR -84.45M
    Pretax IncomeEUR -90.60M
    Net IncomeEUR -92.73M
    EBITDAEUR -68.25M
    EBITEUR -73.60M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 45.70% of the EUR 148.72M in total assets.

    Working CapitalEUR 51.21M
    Shareholder EquityEUR 67.96M
    Tangible Book ValueEUR 67.61M
    Total AssetsEUR 148.72M
    Total LiabilitiesEUR 80.77M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After EUR 2.47M of capital spending, operating cash flow left EUR -74.80M of free cash flow.

    Operating Cash FlowEUR -72.33M
    Capital ExpendituresEUR 2.47M
    Free Cash FlowEUR -74.80M
    Depreciation and AmortizationEUR 6.64M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -282.89%.

    Gross Margin54.32%
    Operating Margin-282.89%
    Pretax Margin-303.50%
    Net Margin-310.64%
    EBITDA Margin-228.62%
    EBIT Margin-246.55%
    FCF Margin-250.58%
    Gross Margin (5Y Average)63.57%

    Growth

    Revenue grew 48.11% a year over 3 years.

    Revenue Growth (3Y CAGR)+48.11%
    Revenue Growth (5Y CAGR)+170.65%

    Revenue and profit by year

    Peer Position

    Against 12 similar companies, NYXH has the 4th highest P/S.

    P/S Ratio2.6x vs 1.1x median
    ROIC-65.86% vs -28.34% median
    Revenue Growth (Trailing 4 Quarters, YoY)+429.37% vs +13.76% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NYXH

    What is NYXH's market cap?

    Nyxoah has a market cap of $91.61M.

    How many shares of NYXH are outstanding?

    Nyxoah has 100.87M shares outstanding. The count is up 169.50% from a year earlier.

    Does NYXH pay a dividend?

    No. Nyxoah does not pay a dividend.